Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KZR-616 in Systemic Lupus Erythematosus with and without Nephritis
NCT03393013Phase 2Completed
- Sponsor
- Kezar Life Sciences
- Start
- Feb 2018
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, open-label trial of zetomipzomib in systemic lupus erythematosus (SLE) and lupus nephritis (LN) (7 arms), sponsored by Kezar Life Sciences. Primary endpoints: Number of Patients Who Experienced at Least One Treatment-Related Treatment-Emergent Adverse Event at 25 weeks and Number of Patients With Lupus Nephritis With a 50% Reduction in UPCR at 24 weeks. Started Feb 2018; status: completed.
02
Drugs
zetomipzomib
03
Conditions
systemic lupus erythematosus (SLE)lupus nephritis (LN)
Beyond the preview
Go deeper on NCT03393013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03393013.